|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeng H, Zheng R, Zhang S, Zou X and Chen
W: Incidence and mortality of female breast cancer in China, 2009.
Thorac Cancer. 4:400–404. 2013. View Article : Google Scholar
|
|
3
|
Thakur A, Rahman KW, Wu J, Bollig A,
Biliran H, Lin X, Nassar H, Grignon DJ, Sarkar FH and Liao JD:
Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in
breast cancer. Mol Cancer Res. 5:171–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yntema HG, van den Helm B, Kissing J, van
Duijnhoven G, Poppelaars F, Chelly J, Moraine C, Fryns JP, Hamel
BC, Heilbronner H, et al: A novel ribosomal S6-kinase (RSK4;
RPS6KA6) is commonly deleted in patients with complex X-linked
mental retardation. Genomics. 62:332–343. 1999. View Article : Google Scholar
|
|
5
|
Kohn M, Hameister H, Vogel M and
Kehrer-Sawatzki H: Expression pattern of the Rsk2, Rsk4 and Pdk1
genes during murine embryogenesis. Gene Expr Patterns. 3:173–177.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Myers AP, Corson LB, Rossant J and Baker
JC: Characterization of mouse Rsk4 as an inhibitor of fibroblast
growth factor-RAS-extracellular signal-regulated kinase signaling.
Mol Cell Biol. 24:4255–4266. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dümmler BA, Hauge C, Silber J, Yntema HG,
Kruse LS, Kofoed B, Hemmings BA, Alessi DR and Frödin M: Functional
characterization of human RSK4, a new 90-kDa ribosomal S6 kinase,
reveals constitutive activation in most cell types. J Biol Chem.
280:13304–13314. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Niehof M and Borlak J: RSK4 and PAK5 are
novel candidate genes in diabetic rat kidney and brain. Mol
Pharmacol. 67:604–611. 2005. View Article : Google Scholar
|
|
9
|
López-Vicente L, Armengol G, Pons B, Coch
L, Argelaguet E, Lleonart M, Hernández-Losa J, de Torres I and
Ramon y Cajal S: Regulation of replicative and stress-induced
senescence by RSK4, which is downregulated in human tumors. Clin
Cancer Res. 15:4546–4553. 2009. View Article : Google Scholar
|
|
10
|
Dewdney SB, Rimel BJ, Thaker PH, Thompson
DM Jr, Schmidt A, Huettner P, Mutch DG, Gao F and Goodfellow PJ:
Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6
(RSK4) in endometrial cancers. Clin Cancer Res. 17:2120–2129. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arechavaleta-Velasco F, Zeferino-Toquero
M, Estrada-Moscoso I, Imani-Razavi FS, Olivares A, Perez-Juarez CE
and Diaz-Cueto L: Ribosomal S6 kinase 4 (RSK4) expression in
ovarian tumors and its regulation by antineoplastic drugs in
ovarian cancer cell lines. Med Oncol. 33:112016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
López-Vicente L, Pons B, Coch L, Teixidó
C, Hernández-Losa J and Armengol G: RSK4 inhibition results in
bypass of stress-induced and oncogene-induced senescence.
Carcinogenesis. 32:470–476. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Q, Jiang Y, Wei W, Ji Y, Gao H and Liu
J: Frequent epigenetic inactivation of RSK4 by promoter methylation
in cancerous and non-cancerous tissues of breast cancer. Med Oncol.
31:7932014. View Article : Google Scholar
|
|
14
|
Zhu J, Li QY, Liu JL, Wei W, Yang HW and
Tang W: RSK4 knockdown promotes proliferation, migration and
metastasis of human breast adenocarcinoma cells. Oncol Rep.
34:3156–3162. 2015.PubMed/NCBI
|
|
15
|
Frödin M and Gammeltoft S: Role and
regulation of 90 kDa ribosomal S6 kinase (RSK) in signal
transduction. Mol Cell Endocrinol. 151:65–77. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roy P and Jacobson K: Overexpression of
profilin reduces the migration of invasive breast cancer cells.
Cell Motil Cytoskeleton. 57:84–95. 2004. View Article : Google Scholar
|
|
17
|
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD
and Wang LH: Twist transcriptionally up-regulates AKT2 in breast
cancer cells leading to increased migration, invasion, and
resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
DeSantis CE, Fedewa SA, Goding Sauer A,
Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015:
Convergence of incidence rates between black and white women. CA
Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar
|
|
19
|
Inoue K and Fry EA: Novel molecular
markers for breast cancer. Biomark Cancer. 8:25–42. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sever R and Brugge JS: Signal transduction
in cancer. Cold Spring Harb Perspect Med. Apr 1–2015.Epub ahead of
print. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu Z, Ye S, Hu G, Lv M, Tu Z, Zhou K and
Li Q: The RAF-MEK-ERK pathway: Targeting ERK to overcome obstacles
to effective cancer therapy. Future Med Chem. 7:269–289. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Navolanic PM, Steelman LS and McCubrey JA:
EGFR family signaling and its association with breast cancer
development and resistance to chemotherapy (Review). Int J Oncol.
22:237–252. 2003.PubMed/NCBI
|
|
23
|
Alvarez RH, Valero V and Hortobagyi GN:
Emerging targeted therapies for breast cancer. J Clin Oncol.
28:3366–3379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Felipe Lima J, Nofech-Mozes S, Bayani J
and Bartlett JM: EMT in breast carcinoma - A review. J Clin Med.
5:652016. View Article : Google Scholar
|
|
25
|
Basse C and Arock M: The increasing roles
of epigenetics in breast cancer: Implications for pathogenicity,
biomarkers, prevention and treatment. Int J Cancer. 137:2785–2794.
2015. View Article : Google Scholar
|
|
26
|
Hoque MO, Prencipe M, Poeta ML, Barbano R,
Valori VM, Copetti M, Gallo AP, Brait M, Maiello E, Apicella A, et
al: Changes in CpG islands promoter methylation patterns during
ductal breast carcinoma progression. Cancer Epidemiol Biomarkers
Prev. 18:2694–2700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park SY, Seo AN, Jung HY, Gwak JM, Jung N,
Cho NY and Kang GH: Alu and LINE-1 hypomethylation is associated
with HER2 enriched subtype of breast cancer. PLoS One.
9:e1004292014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hedenfalk I, Duggan D, Chen Y, Radmacher
M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M,
Kallioniemi OP, et al: Gene-expression profiles in hereditary
breast cancer. N Engl J Med. 344:539–548. 2001. View Article : Google Scholar : PubMed/NCBI
|
